By co-loading photosensitizers and Toll-like receptor 7 agonists, they are able to enhance the efficacy of combined tumor immunotherapy by generating reactive oxygen species (ROS) to kill tumor cells in combination with photodynamic therapy and activating the host’s antitumor immune response to remove residual tumor cells (21). The gene discussed is TLR7; the disease is neoplasm.